324.71
0.00
(0.00%)
At close: July 21 at 6:54:15 PM GMT+1
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 9 | 9 | 15 | 16 |
Avg. Estimate | 15.08B | 14.18B | 57.37B | 59.86B |
Low Estimate | 14.08B | 13.8B | 55.38B | 53.17B |
High Estimate | 15.93B | 14.63B | 61.1B | 66.62B |
Year Ago Sales | 14.21B | 12.73B | 53.51B | 57.37B |
Sales Growth (year/est) | 6.11% | 11.38% | 7.20% | 4.34% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
0R3G.L | -- | -- | -- | -- |
S&P 500 | 9.34% | 11.25% | 14.04% | 13.55% |
Upgrades & Downgrades
Maintains | Barclays: Overweight to Overweight | 1/16/2025 |
Maintains | Morgan Stanley: Overweight to Overweight | 1/16/2025 |
Maintains | Keefe, Bruyette & Woods: Outperform to Outperform | 1/16/2025 |
Maintains | JP Morgan: Overweight to Overweight | 1/16/2025 |
Maintains | Barclays: Overweight to Overweight | 1/6/2025 |
Downgrade | UBS: Buy to Neutral | 1/6/2025 |